Market Overview:
The global poliovirus vaccine inactivated market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth of this market is mainly attributed to the increasing incidence of polio and the subsequent increase in demand for poliovirus vaccine inactivated products. In addition, the increasing focus on preventive healthcare and rising awareness about immunization are also contributing to the growth of this market. However, factors such as high cost and lack of availability in some regions are restraining the growth of this market. On the basis of type, human diploid cell segment is expected to account for a major share of the global poliovirus vaccine inactivated market during 2018-2030. This segment is anticipated to grow at a CAGR 6% during 2018-2030 owing to its advantages over other types such as monkey kidney cell and chick embryo fibroblast cells with respect to production scale, purity, safety, and efficacy. On the basis application, public segment accounted for majority share (over 60%)of global polio virus vaccine sales revenue generated by manufacturers through distribution channels including hospitals & clinics)in 2017; however it will lose its dominant position by 2027 owing declining birth rates across developed economies leading parents opting vaccination privately rather than relying on government funded programs .Regionally North America commanded largest revenue share (~35%) followed by Europe (~25%)and Asia Pacific region (~15%).
Product Definition:
Poliovirus vaccine inactivated is a vaccine used to prevent poliomyelitis. It is administered by injection into the muscle.
Human Diploid Cell:
Human diploid cell, it's usage and growth factor in poliovirus vaccine inactivated is a research study by the scientists of Medicine Research Institute, Korea. The research study aims at finding out the human diploid cell culture for vaccine development against polio virus.
Monkey Kidney Cell:
Monkey kidney cell (KSC) is a type of cell that is used in the production of vaccines for polio. It was first used to produce oral vaccine against polio in humans and has been extensively used ever since. The primary function of this cell line is to provide an effective method for the production of safe, abundant, and highly purified protein as well as maintaining high levels of expression from allofolic acid-related enzymes required for purification & recovery.
Application Insights:
The public sector accounted for the largest share of more than 60.0% in 2017. This is attributed to the fact that most of the countries have started immunization program against poliovirus, which eventually led to its eradication from most of the regions, including Europe and North America.
However, after a gap of nearly two decades since its eradication from these regions, a new wave of poliovirus infections has emerged with an increased number being reported from India and Pakistan in recent years. This trend is expected to continue over next few years untilpolio remains endemic only in three remaining polio-free countries: Afghanistan, Nigeria and Pakistan (see Figure 1).
Regional Analysis:
The global poliovirus vaccine inactivated market is dominated by the North American region, which accounted for a share of over 60.0% in 2017. This can be attributed to the fact that most of the countries have eradicated polio from their territories and hence there is no longer a need for immunization drives or mass vaccination programs as they did in past years. The U.S.
Asia Pacific region is expected to witness lucrative growth over the forecast period owing to increasing incidence rates coupled with large-scale importation from infected nations like India and Pakistan across various regions including Europe.
Growth Factors:
- Increasing incidence of poliomyelitis: The increasing incidence of poliomyelitis is one of the major growth drivers for the global Poliovirus Vaccine Inactivated market. According to the World Health Organization (WHO), there were around 350,000 cases of polio reported in 1988, which reduced to 223 cases in 2016. This indicates a decline in the number of polio cases by over 60%. However, there is still a need for better preventive measures against polio and this is expected to drive demand for Poliovirus Vaccine Inactivated products over the forecast period.
- Growing awareness about benefits of vaccination: There has been a growing awareness about the benefits of vaccination among people across all age groups in recent years. This has led to an increase in demand for various types of vaccines including Poliovirus Vaccine Inactivated products. Furthermore, governments across different countries are also investing heavily towards immunization programs and this is expected to boost growth prospects for the global Poliovirus Vaccine Inactivated market during the forecast period.
- Technological advancements: The development and introduction of new technologies such as recombinant technology have helped improve production efficiency and quality standards pertaining to Poliovirus Vaccine Inactivated products globally. Moreover, these technological advancements are also helping reduce manufacturing costs associated with these vaccines, thereby propelling their uptake globally over time-frame considered herein..
Scope Of The Report
Report Attributes
Report Details
Report Title
Poliovirus Vaccine Inactivated Market Research Report
By Type
Human Diploid Cell, Monkey Kidney Cell
By Application
Public, Private
By Companies
Sanofi, GSK, Serum Institute (Bilthoven Biologicals), IMBCA
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Poliovirus Vaccine Inactivated Market Report Segments:
The global Poliovirus Vaccine Inactivated market is segmented on the basis of:
Types
Human Diploid Cell, Monkey Kidney Cell
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Public, Private
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- GSK
- Serum Institute (Bilthoven Biologicals)
- IMBCA
Highlights of The Poliovirus Vaccine Inactivated Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Human Diploid Cell
- Monkey Kidney Cell
- By Application:
- Public
- Private
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Poliovirus Vaccine Inactivated Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Poliovirus vaccine is inactivated by a process that destroys the virus.
Some of the major companies in the poliovirus vaccine inactivated market are Sanofi, GSK, Serum Institute (Bilthoven Biologicals), IMBCA.
The poliovirus vaccine inactivated market is expected to grow at a compound annual growth rate of 5.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Poliovirus Vaccine Inactivated Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Poliovirus Vaccine Inactivated Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Poliovirus Vaccine Inactivated Market - Supply Chain
4.5. Global Poliovirus Vaccine Inactivated Market Forecast
4.5.1. Poliovirus Vaccine Inactivated Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Poliovirus Vaccine Inactivated Market Size (000 Units) and Y-o-Y Growth
4.5.3. Poliovirus Vaccine Inactivated Market Absolute $ Opportunity
5. Global Poliovirus Vaccine Inactivated Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Type
5.3.1. Human Diploid Cell
5.3.2. Monkey Kidney Cell
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Poliovirus Vaccine Inactivated Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Application
6.3.1. Public
6.3.2. Private
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Poliovirus Vaccine Inactivated Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Poliovirus Vaccine Inactivated Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Poliovirus Vaccine Inactivated Demand Share Forecast, 2019-2026
9. North America Poliovirus Vaccine Inactivated Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Application
9.4.1. Public
9.4.2. Private
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Type
9.7.1. Human Diploid Cell
9.7.2. Monkey Kidney Cell
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Poliovirus Vaccine Inactivated Demand Share Forecast, 2019-2026
10. Latin America Poliovirus Vaccine Inactivated Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Application
10.4.1. Public
10.4.2. Private
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Type
10.7.1. Human Diploid Cell
10.7.2. Monkey Kidney Cell
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Poliovirus Vaccine Inactivated Demand Share Forecast, 2019-2026
11. Europe Poliovirus Vaccine Inactivated Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Application
11.4.1. Public
11.4.2. Private
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Type
11.7.1. Human Diploid Cell
11.7.2. Monkey Kidney Cell
11.8. Basis Point Share (BPS) Analysis y Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Poliovirus Vaccine Inactivated Demand Share, 2019-2026
12. Asia Pacific Poliovirus Vaccine Inactivated Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Application
12.4.1. Public
12.4.2. Private
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Type
12.7.1. Human Diploid Cell
12.7.2. Monkey Kidney Cell
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Poliovirus Vaccine Inactivated Demand Share, 2019-2026
13. Middle East & Africa Poliovirus Vaccine Inactivated Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Application
13.4.1. Public
13.4.2. Private
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Poliovirus Vaccine Inactivated Market Size and Volume Forecast by Type
13.7.1. Human Diploid Cell
13.7.2. Monkey Kidney Cell
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Poliovirus Vaccine Inactivated Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Poliovirus Vaccine Inactivated Market: Market Share Analysis
14.2. Poliovirus Vaccine Inactivated Distributors and Customers
14.3. Poliovirus Vaccine Inactivated Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Sanofi
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. GSK
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Serum Institute (Bilthoven Biologicals)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. IMBCA
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
